Search Result

Results for "

dermatological

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (7) Autophagy (2) Bacterial (7) Biochemical Assay Reagents (4) Estrogen Receptor/ERR (1) Fungal (2) HIV (2) Isotope-Labeled Compounds (3) Parasite (5) Phosphodiesterase (PDE) (3) Reactive Oxygen Species (ROS) (5) Reference Standards (4) Stearoyl-CoA Desaturase (SCD) (1) Tyrosinase (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (2) Endocrinology (1) Infection (7) Inflammation/Immunology (10) Metabolic Disease (1)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W020755

Thiohexam	Biochemical Assay Reagents	Others
Thiohexam is a rubber cure accelerator. Thiohexam is also a known allergen and dermatological sensitizer .

HY-135737

Dicaprylyl carbonate 1 Publications Verification Dioctyl carbonate	Biochemical Assay Reagents	Others
Dicaprylyl carbonate, a solid, plant-derived fat, is a dry emollient. Dicaprylyl carbonate has excellent dermatological compatibility and a comprehensive performance profile, such as solubilizing and dispersing ability for sun-care filters .

HY-B0688

Dapsone 3 Publications Verification 4,4′-Diaminodiphenyl sulfone; DDS	Antibiotic Parasite Bacterial Reactive Oxygen Species (ROS)	Infection Inflammation/Immunology
Dapsone (4,4′-Diaminodiphenyl sulfone) is an orally active and blood-brain penetrant sulfonamide antibiotic with bacteriostatic, antimycobacterial and antiprotozoal activities . Dapsone?exerts effective antileprosy activity?and inhibits folate synthesis in cell extracts of?M. leprae. Dapsone is used for dermatologic disorder research, including leprosy, dermatitis herpetiformis, acne vulgaris et al .

HY-B0688R

Dapsone (Standard) 4,4′-Diaminodiphenyl sulfone (Standard); DDS (Standard)	Reference Standards Antibiotic Parasite Bacterial Reactive Oxygen Species (ROS)	Infection Inflammation/Immunology
Dapsone (Standard) is the analytical standard of Dapsone. This product is intended for research and analytical applications. Dapsone (4,4′-Diaminodiphenyl sulfone) is an orally active and blood-brain penetrant sulfonamide antibiotic with bacteriostatic, antimycobacterial and antiprotozoal activities . Dapsone exerts effective antileprosy activity and inhibits folate synthesis in cell extracts of M. leprae. Dapsone is used for dermatologic disorder research, including leprosy, dermatitis herpetiformis, acne vulgaris et al .

HY-W020755R

Thiohexam (Standard)	Biochemical Assay Reagents Reference Standards	Others
Thiohexam (Standard) is the analytical standard of Thiohexam. This product is intended for research and analytical applications. Thiohexam is a rubber cure accelerator. Thiohexam is also a known allergen and dermatological sensitizer .

HY-113840

Sumarotene Ro 14-9706	Others	Metabolic Disease Inflammation/Immunology
Sumarotene (Ro 14-9706), an arotinoid methyl sulfone, is a potent dermatologic agent for the repair of photodamage, antikeratinization, and antiproliferation. Sumarotene exhibits in rats a prolactin-suppressive activity which affects lactation .

HY-W560402

α-Irone	Others	Others
α-Irone is a compound used as a fragrance ingredient that was evaluated toxicologically and dermatologically.

HY-116939

(E)-Broparestrol	Estrogen Receptor/ERR	Cancer
(E)-Broparestrol is a biologically active tetrasubstituted olefin, which is used as an estrogen in dermatology .

HY-177077

Davalomilast	Phosphodiesterase (PDE)	Inflammation/Immunology
Davalomilast (Example 100) is an PDE4 inhibitor with anti-inflammatory property. Davalomilast can be studied in research for autoimmune diseases and dermatology research .

HY-150125

SCD1-IN-1	Stearoyl-CoA Desaturase (SCD)	Inflammation/Immunology
SCD1-IN-1 is a SCD1 inhibitor (IC₅₀: 5.8 nM). SCD1-IN-1 can be used in the research of dermatologic condition .

HY-119928

Broparestrol	Biochemical Assay Reagents	Cancer
Broparestrol is a biologically active tetrasubstituted olefin can be achieved via palladium-catalyzed cross-coupling to form a C-C bond followed by bromination. Broparestrol inhibits mammary carcinogenesis in mouse model. Broparestrol can be used in dermatology and cancer research .

HY-B0688S1

Dapsone-d4 4,4′-Diaminodiphenyl sulfone-d₄; DDS-d₄	Isotope-Labeled Compounds Antibiotic Parasite Bacterial Reactive Oxygen Species (ROS)	Infection Inflammation/Immunology
Dapsone-d₄ is the deuterium labeled Dapsone. Dapsone (4,4′-Diaminodiphenyl sulfone) is an orally active and blood-brain penetrant sulfonamide antibiotic with bacteriostatic, antimycobacterial and antiprotozoal activities . Dapsone?exerts effective antileprosy activity?and inhibits folate synthesis in cell extracts of?M. leprae. Dapsone is used for dermatologic disorder research, including leprosy, dermatitis herpetiformis, acne vulgaris et al .

HY-N7123

Sulfacetamide 2 Publications Verification Sulphacetamide	Antibiotic Bacterial Fungal	Infection Inflammation/Immunology
Sulfacetamide (Sulphacetamide) is a sulfonamide antibiotic. Sulfacetamide has antifungal and antibacterial activities. Sulfacetamide is employed as a topical formulation in various ophthalmic, dermatological, and hair solutions against bacterial infections, acne and scalp conditions. Sulfacetamide targets bacterial folic acid synthesis and is effective against various gram-positive and gram-negative bacteria. Sulfacetamide inhibits the synthesis of both dihydro-folic acid and para-aminobenzoic acid. Sulfacetamide can be used for the study of ocular infections .

HY-B0688S2

Dapsone-13C12 4,4′-Diaminodiphenyl sulfone-¹³C₁₂; DDS-¹³C₁₂	Isotope-Labeled Compounds Antibiotic Parasite Bacterial Reactive Oxygen Species (ROS)	Infection Inflammation/Immunology
Dapsone- ¹³C₁₂ is the ¹³C₁₂ labeled Dapsone (HY-B0688). Dapsone (4,4′-Diaminodiphenyl sulfone) is an orally active and blood-brain penetrant sulfonamide antibiotic with bacteriostatic, antimycobacterial and antiprotozoal activities. Dapsone exerts effective antileprosy activity and inhibits folate synthesis in cell extracts of M. leprae. Dapsone is used for dermatologic disorder research, including leprosy, dermatitis herpetiformis, acne vulgaris et al .

HY-B0688S3

Dapsone-15N2 4,4′-Diaminodiphenyl sulfone-¹⁵N₂; DDS-¹⁵N₂	Isotope-Labeled Compounds Antibiotic Reactive Oxygen Species (ROS) Bacterial Parasite	Infection Inflammation/Immunology
Dapsone- ¹⁵N₂ (4,4′-Diaminodiphenyl sulfone- ¹⁵N₂) is ¹⁵N labeled Dapsone. Dapsone (4,4′-Diaminodiphenyl sulfone) is an orally active and blood-brain penetrant sulfonamide antibiotic with bacteriostatic, antimycobacterial and antiprotozoal activities . Dapsone?exerts effective antileprosy activity?and inhibits folate synthesis in cell extracts of?M. leprae. Dapsone is used for dermatologic disorder research, including leprosy, dermatitis herpetiformis, acne vulgaris et al .

HY-168436

Tyrosinase-IN-40	Tyrosinase	Endocrinology
Tyrosinase-IN-40 (Compound 9r) is a competitive-type tyrosinase inhibitor, with an IC₅₀ value of 17.02 µM, a K_i value of 14.87 µM. Tyrosinase-IN-40 displays antioxidant activity. Tyrosinase-IN-40 can be used in melanin-related studies .

HY-N7123R

Sulfacetamide (Standard) Sulphacetamide (Standard)	Reference Standards Antibiotic Bacterial Fungal	Infection Inflammation/Immunology
Sulfacetamide (Standard) (Sulphacetamide (Standard)) is the analytical standard of Sulfacetamide (HY-N7123). This product is intended for research and analytical applications. Sulfacetamide (Sulphacetamide) is a sulfonamide antibiotic. Sulfacetamide has antifungal and antibacterial activities. Sulfacetamide is employed as a topical formulation in various ophthalmic, dermatological, and hair solutions against bacterial infections, acne and scalp conditions. Sulfacetamide targets bacterial folic acid synthesis and is effective against various gram-positive and gram-negative bacteria. Sulfacetamide inhibits the synthesis of both dihydro-folic acid and para-aminobenzoic acid. Sulfacetamide can be used for the study of ocular infections .

HY-B0715

Pentoxifylline Maximum Cited Publications 8 Publications Verification BL-191; PTX; Oxpentifylline	Phosphodiesterase (PDE) Autophagy HIV	Cardiovascular Disease Cancer
Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

HY-B0715R

Pentoxifylline (Standard) BL-191 (Standard); PTX (Standard); Oxpentifylline (Standard)	HIV Autophagy Phosphodiesterase (PDE) Reference Standards	Cardiovascular Disease Cancer
Pentoxifylline (Standard) is the analytical standard of Pentoxifylline. This product is intended for research and analytical applications. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

Cat. No.	Product Name

HY-L141

Off-patent Drug Library	2,773 compounds
Drug repurposing (also called drug repositioning, reprofiling, or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, for example, lower risk of failure, less investment, and shorter development timelines. But drug repositioning projects are also subject to several risks, including regulatory and intellectual property issues. So the off-patent drugs are optimal for repositioning because of their immediate availability for clinical studies, with high feasibility and relatively low risk. MCE carefully prepared a unique collection of 2,773 off-patent drugs, which is a good choice for drug repurposing.

Off-patent Drug Library

2,773 compounds

Drug repurposing (also called drug repositioning, reprofiling, or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, for example, lower risk of failure, less investment, and shorter development timelines. But drug repositioning projects are also subject to several risks, including regulatory and intellectual property issues. So the off-patent drugs are optimal for repositioning because of their immediate availability for clinical studies, with high feasibility and relatively low risk.

MCE carefully prepared a unique collection of 2,773 off-patent drugs, which is a good choice for drug repurposing.

HY-L035P

Drug Repurposing Compound Library Plus	6,116 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved and clinical drugs, especially after phase I drugs, have identified bioactivities, good pharmacokinetic characteristics and safety, which are suitable for drug repurposing. MCE Drug Repurposing Compound Library plus contains 6,116 approved and passed phase I clinical drugs, which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE Drug Repurposing Compound Library plus, with more powerful screening capability, further complement MCE Drug Repurposing Compound Library (HY-L035) by adding some compounds with low solubility or stability (Part B) to this library. All those supplementary compounds are supplied in powder form.

Drug Repurposing Compound Library Plus

6,116 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved and clinical drugs, especially after phase I drugs, have identified bioactivities, good pharmacokinetic characteristics and safety, which are suitable for drug repurposing.

MCE Drug Repurposing Compound Library plus contains 6,116 approved and passed phase I clinical drugs, which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties.

MCE Drug Repurposing Compound Library plus, with more powerful screening capability, further complement MCE Drug Repurposing Compound Library (HY-L035) by adding some compounds with low solubility or stability (Part B) to this library. All those supplementary compounds are supplied in powder form.

HY-L035

Drug Repurposing Compound Library	5,135 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved and clinical drugs, especially after phase I drugs, have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE Drug Repurposing Compound Library contains 5,135 approved drugs and passed phase Ⅰclinical drugs, which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties.

Drug Repurposing Compound Library

5,135 compounds

MCE Drug Repurposing Compound Library contains 5,135 approved drugs and passed phase Ⅰclinical drugs, which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties.

HY-L053

NMPA-Approved Drug Library	1,395 compounds
From target identification to clinical research, traditional drug discovery and development is a time-consuming and costly process, which also bears high risk. Compared with traditional drug discovery, drug repositioning or repurposing, also known as old drugs for new uses can greatly shorten the development cycle and reduce development cost, which has become a new trend of drug development. After undergoing clinical trials, approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety, which can greatly improve the success rate of drug discovery. A number of successes have been achieved, such as metformin for type 2 diabetes and thalidomide for leprosy and multiple myeloma, etc. MCE provides a unique collection of 1,395 China NMPA (National Medical Products Administration) approved compounds, which have undergone extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE NMPA-Approved Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.

NMPA-Approved Drug Library

1,395 compounds

From target identification to clinical research, traditional drug discovery and development is a time-consuming and costly process, which also bears high risk. Compared with traditional drug discovery, drug repositioning or repurposing, also known as old drugs for new uses can greatly shorten the development cycle and reduce development cost, which has become a new trend of drug development. After undergoing clinical trials, approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety, which can greatly improve the success rate of drug discovery. A number of successes have been achieved, such as metformin for type 2 diabetes and thalidomide for leprosy and multiple myeloma, etc.

MCE provides a unique collection of 1,395 China NMPA (National Medical Products Administration) approved compounds, which have undergone extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE NMPA-Approved Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.

HY-L022P

FDA-Approved Drug Library Plus	3,511 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE owns a unique collection of 3,511 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE FDA-Approved Drug Library Plus, with more powerful screening capability, further complements FDA-Approved Drug Library (HY-L022) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

FDA-Approved Drug Library Plus

3,511 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.

MCE owns a unique collection of 3,511 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE FDA-Approved Drug Library Plus, with more powerful screening capability, further complements FDA-Approved Drug Library (HY-L022) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

HY-L022

FDA-Approved Drug Library	3,095 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE owns a unique collection of 3,095 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE FDA-Approved Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.

FDA-Approved Drug Library

3,095 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.

MCE owns a unique collection of 3,095 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE FDA-Approved Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.

HY-L066

FDA Approved & Pharmacopeial Drug Library	3,584 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or retasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs and pharmacopoeia collected compounds have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE owns a unique collection of 3,584 compounds from approved institutions such as FDA, EMA, NMPA, PMDA, etc. or pharmacopoeia such as USP, BP, JP, etc. These compounds have well-characterized bioactivities, safety and bioavailability properties. MCE FDA Approved & Pharmacopeial Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.

FDA Approved & Pharmacopeial Drug Library

3,584 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or retasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs and pharmacopoeia collected compounds have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.

MCE owns a unique collection of 3,584 compounds from approved institutions such as FDA, EMA, NMPA, PMDA, etc. or pharmacopoeia such as USP, BP, JP, etc. These compounds have well-characterized bioactivities, safety and bioavailability properties. MCE FDA Approved & Pharmacopeial Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.

HY-L022M

FDA-Approved Drug Library Mini	3,095 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE owns a unique collection of 3,095 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. The package of this library is 96-well microplate with peelable foil seal, which makes the screening process easier and faster.

FDA-Approved Drug Library Mini

3,095 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.

MCE owns a unique collection of 3,095 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. The package of this library is 96-well microplate with peelable foil seal, which makes the screening process easier and faster.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-135737

Dicaprylyl carbonate 1 Publications Verification Dioctyl carbonate	Structural Classification Natural Products other families Classification of Application Fields Source classification Other Diseases Plants Disease Research Fields	Biochemical Assay Reagents
Dicaprylyl carbonate, a solid, plant-derived fat, is a dry emollient. Dicaprylyl carbonate has excellent dermatological compatibility and a comprehensive performance profile, such as solubilizing and dispersing ability for sun-care filters .

HY-N7123

Sulfacetamide 2 Publications Verification Sulphacetamide	Infection Classification of Application Fields Disease Research Fields	Antibiotic Bacterial Fungal
Sulfacetamide (Sulphacetamide) is a sulfonamide antibiotic. Sulfacetamide has antifungal and antibacterial activities. Sulfacetamide is employed as a topical formulation in various ophthalmic, dermatological, and hair solutions against bacterial infections, acne and scalp conditions. Sulfacetamide targets bacterial folic acid synthesis and is effective against various gram-positive and gram-negative bacteria. Sulfacetamide inhibits the synthesis of both dihydro-folic acid and para-aminobenzoic acid. Sulfacetamide can be used for the study of ocular infections .

HY-B0715

Pentoxifylline Maximum Cited Publications 8 Publications Verification BL-191; PTX; Oxpentifylline	Classification of Application Fields Disease Research Fields Cancer	Phosphodiesterase (PDE) Autophagy HIV
Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

Cat. No.	Product Name	Chemical Structure

HY-B0688S1

Dapsone-d4
Dapsone-d₄ is the deuterium labeled Dapsone. Dapsone (4,4′-Diaminodiphenyl sulfone) is an orally active and blood-brain penetrant sulfonamide antibiotic with bacteriostatic, antimycobacterial and antiprotozoal activities . Dapsone?exerts effective antileprosy activity?and inhibits folate synthesis in cell extracts of?M. leprae. Dapsone is used for dermatologic disorder research, including leprosy, dermatitis herpetiformis, acne vulgaris et al .

Dapsone-d4

Dapsone-d₄ is the deuterium labeled Dapsone. Dapsone (4,4′-Diaminodiphenyl sulfone) is an orally active and blood-brain penetrant sulfonamide antibiotic with bacteriostatic, antimycobacterial and antiprotozoal activities . Dapsone?exerts effective antileprosy activity?and inhibits folate synthesis in cell extracts of?M. leprae. Dapsone is used for dermatologic disorder research, including leprosy, dermatitis herpetiformis, acne vulgaris et al .

HY-B0688S2

Dapsone-13C12
Dapsone- ¹³C₁₂ is the ¹³C₁₂ labeled Dapsone (HY-B0688). Dapsone (4,4′-Diaminodiphenyl sulfone) is an orally active and blood-brain penetrant sulfonamide antibiotic with bacteriostatic, antimycobacterial and antiprotozoal activities. Dapsone exerts effective antileprosy activity and inhibits folate synthesis in cell extracts of M. leprae. Dapsone is used for dermatologic disorder research, including leprosy, dermatitis herpetiformis, acne vulgaris et al .

Dapsone-13C12

Dapsone- ¹³C₁₂ is the ¹³C₁₂ labeled Dapsone (HY-B0688). Dapsone (4,4′-Diaminodiphenyl sulfone) is an orally active and blood-brain penetrant sulfonamide antibiotic with bacteriostatic, antimycobacterial and antiprotozoal activities. Dapsone exerts effective antileprosy activity and inhibits folate synthesis in cell extracts of M. leprae. Dapsone is used for dermatologic disorder research, including leprosy, dermatitis herpetiformis, acne vulgaris et al .

HY-B0688S3

Dapsone-15N2
Dapsone- ¹⁵N₂ (4,4′-Diaminodiphenyl sulfone- ¹⁵N₂) is ¹⁵N labeled Dapsone. Dapsone (4,4′-Diaminodiphenyl sulfone) is an orally active and blood-brain penetrant sulfonamide antibiotic with bacteriostatic, antimycobacterial and antiprotozoal activities . Dapsone?exerts effective antileprosy activity?and inhibits folate synthesis in cell extracts of?M. leprae. Dapsone is used for dermatologic disorder research, including leprosy, dermatitis herpetiformis, acne vulgaris et al .

Dapsone-15N2

Dapsone- ¹⁵N₂ (4,4′-Diaminodiphenyl sulfone- ¹⁵N₂) is ¹⁵N labeled Dapsone. Dapsone (4,4′-Diaminodiphenyl sulfone) is an orally active and blood-brain penetrant sulfonamide antibiotic with bacteriostatic, antimycobacterial and antiprotozoal activities . Dapsone?exerts effective antileprosy activity?and inhibits folate synthesis in cell extracts of?M. leprae. Dapsone is used for dermatologic disorder research, including leprosy, dermatitis herpetiformis, acne vulgaris et al .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

dermatological

Inhibitors & Agonists

Screening Libraries

NaturalProducts

Isotope-Labeled Compounds

Natural
Products